The Director, Pharmacovigilance and Clinical Trial Dr Partha Gurumurthy accompanied by Pharmacovigilance Officers Mr Wapapha Nthomiwa and Ms Elizabeth Kelentse and Public Relations Officer Ms Itumeleng S. Ledimo have set out to Ngamiland DHMT in a mission to sensitise Health Care Providers on Pharmacovigilance and BoMRA services.
Following sensitisation the team shall also launch an Adverse Drug Reaction Monitoring Centre (AMC) at Letsholathebe II Memorial Hospital on the 2nd September 2020. The centre shall be;
- A centralised office for the Ngami DHMT on collection, sensitisation and reporting of ADRs in the region
- Training of Pharmacovigilance
- One of the upcoming 12 centers (satellites) to be established countywide that will decentralize the mandate of BoMRA - Dept. Pharmacovigilance and Clinical Trials.
Do follow us for more updates.